Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer.
Humans
Urinary Bladder Neoplasms
/ drug therapy
BCG Vaccine
/ therapeutic use
Male
Aged
Female
Middle Aged
Neoplasm Invasiveness
Age Factors
Treatment Outcome
Retrospective Studies
Adjuvants, Immunologic
/ therapeutic use
Survival Rate
Aged, 80 and over
Administration, Intravesical
Non-Muscle Invasive Bladder Neoplasms
Age
Cancer
Free survival
Invasive bladder cancer
Muscle
Non
Overall survival
Progression
Recurrence
Specific survival
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
27
06
2024
accepted:
12
08
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
epublish
Résumé
To investigate the impact of ageing on survival outcomes in Bacillus Calmette-Guérin (BCG) treated non-muscle invasive bladder cancer (NMIBC) patients and its synergy with adequate BCG treatment. Patients with NMIBC who received BCG treatment from 2001 to 2020 were divided into group 1 (< = 70 years) and group 2 (> 70 years). Overall Survival (OS), Cancer-Specific Survival (CSS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method. Multivariable Cox regression analysis was used to adjust potential confounding factors and to estimate Hazard Ratio (HR) and 95% Confidence Interval (CI). Subgroup analysis was performed according to adequate versus inadequate BCG treatment. Overall, 2602 NMIBC patients were included: 1051 (40.4%) and 1551 (59.6%) in groups 1 and 2, respectively. At median follow-up of 11.0 years, group 1 (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS as compared to group 2 (> 70 years). At subgroup analysis, patients in group 1 treated with adequate BCG showed better OS, CSS, RFS, and PFS as compared with inadequate BCG treatment in group 2, while patients in group 2 receiving adequate BCG treatment had 41% less progression than those treated with inadequate BCG from the same group. Being younger (< = 70 years) was associated with better OS, CSS, and RFS, but not PFS. Older patients (> 70 years) who received adequate BCG treatment had similar PFS as those younger with adequate BCG treatment.
Identifiants
pubmed: 39331198
doi: 10.1007/s00345-024-05218-4
pii: 10.1007/s00345-024-05218-4
doi:
Substances chimiques
BCG Vaccine
0
Adjuvants, Immunologic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
547Subventions
Organisme : UGC Research Matching Fund
ID : 8601521
Organisme : General Research Fund and Early Career Scheme
ID : 14117421
Informations de copyright
© 2024. The Author(s).
Références
Zhang Y, Rumgay H, Li M, Yu H, Pan H, Ni J (2023) The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health 13:04109
doi: 10.7189/jogh.13.04109
pubmed: 37712386
pmcid: 10502766
Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH (2010) The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 105:300–308
doi: 10.1111/j.1464-410X.2009.09076.x
pubmed: 19912200
Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M (2022) Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol 19:280–294
doi: 10.1038/s41585-022-00578-1
pubmed: 35361927
Kukreja JB (2023) Non-muscle-invasive Bladder Cancer: Side-by-Side Guideline Comparison. Eur Urol Focus. https://doi.org/10.1016/j.euf.2023.05.004
doi: 10.1016/j.euf.2023.05.004
pubmed: 37308343
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH et al (2022) European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 81:75–94
doi: 10.1016/j.eururo.2021.08.010
pubmed: 34511303
Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol 11:153–162
doi: 10.1038/nrurol.2014.15
pubmed: 24492433
Lobo N, Brooks NA, Zlotta AR, Cirillo JD, Boorjian S, Black PC, Meeks JJ, Bivalacqua TJ, Gontero P, Steinberg GD et al (2021) 100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. Nat Rev Urol 18:611–622
doi: 10.1038/s41585-021-00481-1
pubmed: 34131332
pmcid: 8204595
Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, Sengupta S, Mostafid H, Kamat AM, Black PC et al (2020) Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol 78:893–906
doi: 10.1016/j.eururo.2020.09.006
pubmed: 32972792
Hong Kong population projections for 2022–2046 released [ https://www.info.gov.hk/gia/general/202308/15/P2023081500304.htm ]
Hieber C, Grabbe S, Bros M (2023) Counteracting immunosenescence-which therapeutic strategies are promising? Biomolecules 13:1085
doi: 10.3390/biom13071085
pubmed: 37509121
pmcid: 10377144
Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras-Gonzalez GM, Guo CC et al (2023) Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin. BJU Int 133:63–70
doi: 10.1111/bju.16127
pubmed: 37442564
Liu K, Zhao H, Chen X, Nicoletti R, Vasdev N, Chiu PK, Ng CF, Kawada T, Laukhtina E, Mori K et al (2023) A territory-wide study investigating the dose and efficacy of different Bacillus Calmette-Guérin strains in patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2023.09.014
doi: 10.1016/j.euo.2023.09.014
pubmed: 38158249
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978–94–92671–19–6
Kresovich JK, Xu Z, O’Brien KM, Weinberg CR, Sandler DP, Taylor JA (2019) Methylation-based biological age and breast cancer risk. J Natl Cancer Inst 111:1051–1058
doi: 10.1093/jnci/djz020
pubmed: 30794318
pmcid: 6792078
Harrison H, Thompson RE, Lin Z, Rossi SH, Stewart GD, Griffin SJ, Usher-Smith JA (2021) Risk prediction models for kidney cancer: a systematic review. Eur Urol Focus 7:1380–1390
doi: 10.1016/j.euf.2020.06.024
pubmed: 32680829
pmcid: 8642244
Deuker M, Rosiello G, Stolzenbach LF, Martin T, Collà Ruvolo C, Nocera L, Tian Z, Roos FC, Becker A, Kluth LA et al (2021) Sex- and age-related differences in the distribution of metastases in patients with upper urinary tract urothelial carcinoma. J Natl Compr Canc Netw 19:534–540
doi: 10.6004/jnccn.2020.7637
pubmed: 33571954
Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK (2020) Prostate cancer incidence and survival, by stage and race/ethnicity - United States, 2001–2017. MMWR Morb Mortal Wkly Rep 69:1473–1480
doi: 10.15585/mmwr.mm6941a1
pubmed: 33056955
pmcid: 7561091
Herr HW (2007) Age and outcome of superficial bladder cancer treated with Bacille Calmette-Guérin therapy. Urology 70:65–68
doi: 10.1016/j.urology.2007.03.024
pubmed: 17656210
Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Witjes JA, Oosterlinck W (2014) The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol 66:694–701
doi: 10.1016/j.eururo.2014.05.033
pubmed: 24948466
Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766-773
Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Alfred Witjes J, Oosterlinck W (2016) Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance Bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. BJU Int 118:423–428
doi: 10.1111/bju.13474
pubmed: 26945890
Ershler WB, Socinski MA, Greene CJ (1983) Bronchogenic cancer, metastases, and aging. J Am Geriatr Soc 31:673–676
doi: 10.1111/j.1532-5415.1983.tb04153.x
pubmed: 6630826
Fisher CJ, Egan MK, Smith P, Wicks K, Millis RR, Fentiman IS (1997) Histopathology of breast cancer in relation to age. Br J Cancer 75:593–596
doi: 10.1038/bjc.1997.103
pubmed: 9052416
pmcid: 2063298
Gödde D, Degener S, Walles C, Keller R, Graf K, Tosch M, Krege S, Musch M, Kvasnicka HM, Ackermann M, et al: Degenerative changes in aging human pelvic lymph nodes-a reason to rethink staging and therapy of regional malignancies? Cancers (Basel) 2023, 15